Price T Rowe Associates Inc Y M Abs Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 22,537 shares of YMAB stock, worth $183,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,537
Previous 22,279
1.16%
Holding current value
$183,676
Previous $270,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding YMAB
# of Institutions
106Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$33.3 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$24 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$17.9 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$16.6 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$14.9 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $356M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...